• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗甲状腺球蛋白自身抗体(ATG)的频率及临床意义

Frequency and clinical importance of anti-Tg auto-antibodies (ATG).

作者信息

Adil Allah- Rakha, Jafri Rafaqat A, Waqar Amin, Abbasi Siraj A, Asghar A H, Jilani Asif, Naz Irum

机构信息

Department of Nuclear Medicine, LINAR (Larkana Institute of Nuclear Medicine and Radiotherapy), Larkana.

出版信息

J Coll Physicians Surg Pak. 2003 Sep;13(9):504-6.

PMID:12971869
Abstract

OBJECTIVE

To note the frequency of anti thyroglobulin autoantibodies (ATG) and its clinical importance in 25 follow-up cases of differentiated thyroid cancer (DTC).

DESIGN

A case control study.

PLACE AND DURATION OF STUDY

The total duration of study was one year (September 2000 to August 2001). Majority of the patients included were the routine follow-up cases at IRNUM, Peshawar. However, few of the cases were also included from NORI, Islamabad and AFIP, Rawalpindi.

SUBJECTS AND METHODS

All the patients who had undergone sub-total or total thyroidectomy followed by I-131 ablation therapy were selected for this study. Thyroglobulin (Tg) and ATG were measured using immunometric assay technique with reference range of non-detectable to 40 IU/L. Patients with serum Tg level 10 ng/mL were included in group-1 (n=15) and all the remaining (n=10) in group-2.

RESULTS

Overall, 11 patients showed ATG titer above the pre-defined threshold level. In group-1 patients, 8 had positive anti-Tg antibodies in their sera while in group-2, it was positive in only 3 cases. Risk of relapsing metastatic/recurrent disease in association with ATG was calculated which showed that patients with positive ATG have almost seven-fold increased risk of having recurrent/metastatic disease than those who do not.

CONCLUSION

Samples for s-Tg measurements must also be evaluated for ATG status because more than one-third of these patients have positive ATG titer in their sera. Although in the presence of positive ATG, the risk of concurrent metastatic/recurrent thyroid disease is increased but still more studies are required to support its significance.

摘要

目的

观察25例分化型甲状腺癌(DTC)随访病例中抗甲状腺球蛋白自身抗体(ATG)的出现频率及其临床意义。

设计

病例对照研究。

研究地点及时间

研究总时长为一年(2000年9月至2001年8月)。纳入的大多数患者为白沙瓦IRNUM的常规随访病例。不过,也有少数病例来自伊斯兰堡的NORI和拉瓦尔品第的AFIP。

研究对象与方法

本研究选取了所有接受过甲状腺次全切除术或全甲状腺切除术并接受碘-131消融治疗的患者。采用免疫测定技术测量甲状腺球蛋白(Tg)和ATG,参考范围为未检测到至40 IU/L。血清Tg水平>10 ng/mL的患者被纳入第1组(n = 15),其余所有患者(n = 10)被纳入第2组。

结果

总体而言,11例患者的ATG滴度高于预先设定的阈值水平。在第1组患者中,8例血清抗Tg抗体呈阳性,而在第2组中,只有3例呈阳性。计算了与ATG相关的复发转移性/复发性疾病风险,结果显示ATG阳性患者发生复发/转移性疾病的风险几乎是ATG阴性患者的七倍。

结论

对于s-Tg测量的样本,还必须评估其ATG状态,因为超过三分之一的这些患者血清中ATG滴度呈阳性。虽然在ATG阳性的情况下,并发转移性/复发性甲状腺疾病的风险会增加,但仍需要更多研究来支持其重要性。

相似文献

1
Frequency and clinical importance of anti-Tg auto-antibodies (ATG).抗甲状腺球蛋白自身抗体(ATG)的频率及临床意义
J Coll Physicians Surg Pak. 2003 Sep;13(9):504-6.
2
[Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma].[抗甲状腺球蛋白自身抗体的回收率测试或免疫放射测量法用于不同甲状腺癌随访中甲状腺球蛋白测定结果的解读]
Nuklearmedizin. 2001 Oct;40(5):155-63.
3
The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer.联合检测甲状腺球蛋白和抗甲状腺球蛋白抗体对鉴别分化型甲状腺癌患者持续性疾病和复发性疾病的附加临床价值。
Nucl Med Commun. 2008 Oct;29(10):880-4. doi: 10.1097/MNM.0b013e328308e079.
4
[Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].[甲状腺切除术后分化型甲状腺癌患者血清甲状腺球蛋白及抗甲状腺球蛋白抗体的临床意义]
Magy Onkol. 2004;48(1):27-34. Epub 2004 Apr 23.
5
[Anti thyroglobulin antibodies in the follow up of patients with differentiated thyroid cancer: residual or relapsing disease markers?].[分化型甲状腺癌患者随访中的抗甲状腺球蛋白抗体:残余或复发性疾病标志物?]
Rev Med Chil. 2002 Feb;130(2):167-72.
6
Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.分化型甲状腺癌术前血清甲状腺球蛋白检测不到:发生率、原因及管理策略
Clin Endocrinol (Oxf). 2007 Oct;67(4):547-51. doi: 10.1111/j.1365-2265.2007.02922.x. Epub 2007 Jun 11.
7
Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.血清甲状腺球蛋白浓度可预测分化型甲状腺癌的无病缓解和死亡情况。
Clin Endocrinol (Oxf). 2007 Jan;66(1):58-64. doi: 10.1111/j.1365-2265.2006.02685.x.
8
Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.重组人促甲状腺素辅助 131I 消融术前甲状腺球蛋白测定在检测分化型甲状腺癌转移灶中的应用
Clin Endocrinol (Oxf). 2008 Oct;69(4):659-63. doi: 10.1111/j.1365-2265.2008.03244.x. Epub 2008 Mar 18.
9
Importance of measurement of thyroglobulin and anti-thyroglobulin antibodies in differentiated thyroid cancer.分化型甲状腺癌中甲状腺球蛋白和抗甲状腺球蛋白抗体检测的重要性
Coll Antropol. 2012 Nov;36 Suppl 2:33-8.
10
Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.外周促甲状腺素受体mRNA在分化型甲状腺癌随访中的有效性
Ann Surg Oncol. 2009 Feb;16(2):473-80. doi: 10.1245/s10434-008-0211-9. Epub 2008 Nov 18.

引用本文的文献

1
Anti-thyroglobulin antibody levels post-thyroidectomy and papillary thyroid carcinoma recurrence.甲状腺切除术后抗甲状腺球蛋白抗体水平与甲状腺乳头状癌复发
BMC Cancer. 2025 Aug 25;25(1):1371. doi: 10.1186/s12885-025-14709-5.
2
Nomogram for the Prediction of Biochemical Incomplete Response in Papillary Thyroid Cancer Patients.预测甲状腺乳头状癌患者生化不完全缓解的列线图
Cancer Manag Res. 2021 Jul 13;13:5641-5650. doi: 10.2147/CMAR.S320993. eCollection 2021.
3
Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis.
低剂量放射性碘消融在低危和中危分化型甲状腺癌中的疗效:一项回顾性比较分析
J Clin Med. 2020 Feb 21;9(2):581. doi: 10.3390/jcm9020581.
4
Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators.放射性碘治疗及随访期间甲状腺球蛋白持续阴性且甲状腺球蛋白抗体水平升高的甲状腺乳头状癌肺转移:长期结局及预后指标
Front Endocrinol (Lausanne). 2020 Jan 10;10:903. doi: 10.3389/fendo.2019.00903. eCollection 2019.
5
Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.分化型甲状腺癌患者血清抗甲状腺球蛋白抗体的动态变化
Endocrine. 2020 Feb;67(2):387-396. doi: 10.1007/s12020-019-02112-7. Epub 2019 Oct 24.
6
Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer.低风险分化型甲状腺癌患者的低剂量放射性碘消融治疗
Eur Thyroid J. 2018 Aug;7(4):218-224. doi: 10.1159/000489850. Epub 2018 Jul 5.
7
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南:美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
8
Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.采用灵敏的(第二代)免疫测定法对分化型甲状腺癌患者进行血清甲状腺球蛋白(Tg)监测时,血清甲状腺球蛋白自身抗体的假阴性和假阳性误判可能会干扰监测结果。
J Clin Endocrinol Metab. 2014 Dec;99(12):4589-99. doi: 10.1210/jc.2014-1203.
9
Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer.基础血清甲状腺球蛋白水平而非基础抗甲状腺球蛋白抗体(TgAb)水平在分化型甲状腺癌患者中的预后价值
Mol Imaging Radionucl Ther. 2014 Jun;23(2):54-9. doi: 10.4274/mirt.39200. Epub 2014 Jun 5.
10
Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.甲状腺乳头状癌及循环抗甲状腺球蛋白自身抗体患者的临床侵袭性和长期预后
Thyroid. 2014 Jul;24(7):1139-45. doi: 10.1089/thy.2013.0698. Epub 2014 May 21.